ATLANTA, March 29,
2023 /PRNewswire/ -- Sharecare (Nasdaq: SHCR), the
digital health company that helps people manage all their health in
one place, today announced financial results for the quarter and
year ended December 31, 2022.
"We are pleased with our financial performance in the quarter
and over the full year, during which we hit several key milestones
for our core Enterprise business, including contracting over
900,000 new eligible lives for Sharecare+, our digital-first
advocacy solution, and 1.8 million new members for CareLinx, our
tech-enabled home health offering, as well as exceeding our target
KPI for eligible lives with 12.4 million," said Jeff Arnold, chairman and CEO of Sharecare. "Our
foundation is solid, and we are committed to continue growing
Sharecare's eligible lives, increasing our PMPMs, becoming more
profitable, and, most importantly, measurably improving the
well-being of each of our members."
Mr. Arnold added, "Last year, we announced plans to conduct a
strategic review to clearly understand all of the potential options
to maximize our shareholder value. We have expanded the review to
include potential business combinations to complement our thriving
Enterprise channel, which is yielding a growing and robust
pipeline, new customer wins across the employer, payor, and
government sectors as well as high client retention as we continue
to expand our core comprehensive digital platform with our
innovative product offerings. Further, the strategic review has
also affirmed the value of our Provider channel; garnering
attractive valuations on a standalone basis and we continue to
actively evaluate ways to unlock that value, while increasing
profitability through global outsourcing and growing and retaining
clients."
Fourth Quarter 2022 Financial Results
All
comparisons, unless otherwise noted, are to the three months ended
December 31, 2021.
- Revenue of $123.3 million
compared to $118.5 million, an
increase of $4.8 million, or 4%.
- Net loss attributable to Sharecare of $24.1 million compared to net income attributable
to Sharecare of $9.6 million, a
decrease of $33.7 million. Net loss
in the fourth quarter of 2022 included $8.0
million in non-cash stock compensation; $4.5 million in non-operating, non-recurring
costs; $4.6 million of
reorganizational and severance costs; $1.1
million in acquisition-related costs; and $0.6 million of other non-cash or non-operational
expense. Excluding these items, the adjusted net loss was
$5.3 million in the current
quarter.
- Adjusted EBITDA of $4.6 million
compared to $5.4 million, a decrease
of $0.8 million which is primarily
attributable to the sunsetting of the COVID-19 health security
program that had a substantial impact on revenue and adjusted
EBITDA in the prior year period.
- Net loss per share of $0.07
compared to net earnings per share of $0.03, a decrease of $0.10 which reflects the aforementioned items
impacting net income.
- Adjusted net loss per share was $0.02 compared to $0.01, an increase to adjusted net loss per share
of $0.01 which excludes the impact of
non-cash and non-operational income and expenses.
Full Year Financial Results
All comparisons, unless
otherwise noted, are to the twelve months ended December 31,
2021.
- Revenue of $442.4 million
compared to $412.8 million, an
increase of $29.6 million, or
7%.
- Net loss attributable to Sharecare of $118.7 million compared to net loss attributable
to Sharecare of $85.0 million, an
increase to net loss of $33.7
million. Net loss attributable to Sharecare during 2022
included $69.6 million in non-cash
stock compensation; $14.4 million in
non-operating, non-recurring costs; $13.7
million in reorganizational and severance costs;
$5.8 million in acquisition related
costs; and $5.3 million of other
non-cash or non-operational income. Excluding these items, the
adjusted net loss was $20.5 million
in the current year.
- Adjusted EBITDA of $15.8 million
compared to $27.0 million, a decrease
of $11.2 million which, as mentioned
above, is largely a result of the suspended health security
business.
- Net loss per share of $0.34
compared to $0.30, an increase to net
loss per share of $0.04 which
reflects the aforementioned items impacting net loss.
- Adjusted net loss per share of $0.06 compared to $0.04, an increase to adjusted net loss per share
of $0.02 which excludes the impact of
non-cash and non-operational income and expenses.
"We are committed to a balanced approach to growth and margin
and will begin to realize the benefits of the approximately
$30 million in annualized cost
savings as we progress across 2023 thanks to globalization efforts
already in progress within our Enterprise and Provider channels,"
added Arnold. "As we initiate standalone 2023 guidance, I want to
emphasize that we have built our projections for the Enterprise
channel based solely on the business under contract, and modeled
growth for the Provider and Life Sciences channels in line with
their 2022 growth rates. Further, we anticipate nearly doubling our
adjusted EBITDA in 2023 and are confident in our ability to deliver
increased value for our shareholders while ensuring continued
growth and success in the evolving healthcare landscape."
Financial Outlook
Q1 2023 Financial Guidance
For the three months ending
March 31, 2023, the Company
expects:
- Revenue in the range of $111
million to $113 million
- Adjusted EBITDA in the range of $1 to $2
million
Fiscal 2023 Financial Guidance
For the twelve months
ending December 31, 2023, the Company
expects:
- Revenue in the range of $450
million to $460 million
- Adjusted EBITDA in the range of $25
million to $30 million
Supplemental Forward-Looking Expectations and Assumptions for
Fiscal 2023
The Company has determined to provide the
following supplemental expectations and assumptions regarding its
fiscal 2023 results to provide investors with further transparency
into the Company's current beliefs regarding fiscal 2023, all of
which are subject to change.
Our guidance assumptions reflect the following:
- Increase in Enterprise eligible lives to approximately 12.9
million by year-end fiscal 2023, a 4% increase over fiscal
2022.
- Increase in records retrieved to 6.5 million records, a 12%
increase over fiscal 2022.
- Capital expenditures of approximately $30 million.
Conference Call
The Company will host a conference
call to review the fourth quarter and full-year fiscal 2022 results
today, Wednesday, March 29, 2023, at
8:00 a.m. EDT. The call can be
accessed by dialing (833) 636-1352 for U.S. participants or (412)
902-4148 for international participants, and referencing the
Sharecare earnings call; or via live audio webcast, available
online at https://investors.sharecare.com/. A webcast replay of the
call will be available for on-demand listening at the same link and
will remain available for approximately 90 days.
Non-GAAP Financial Measures
In addition to our
financial results determined in accordance with U.S. GAAP, we
believe the non-GAAP measures adjusted EBITDA, adjusted net income
(loss), and adjusted earnings (loss) per share ("adjusted EPS") are
useful in evaluating our operating performance. We use adjusted
EBITDA, adjusted net income (loss), and adjusted EPS to evaluate
our ongoing operations and for internal planning and forecasting
purposes. We believe that these non-GAAP financial measures, when
taken together with the corresponding GAAP financial measures,
provide meaningful supplemental information regarding our
performance by excluding certain items that may not be indicative
of our business, results of operations, or outlook. In particular,
we believe that the use of these non-GAAP measures is helpful to
our investors as these metrics are used by management in assessing
the health of our business and our operating performance. However,
non-GAAP financial information is presented for supplemental
informational purposes only, has limitations as an analytical tool,
and should not be considered in isolation or as a substitute for
financial information presented in accordance with GAAP. In
addition, other companies, including companies in our industry, may
calculate similarly-titled non-GAAP measures differently or may use
other measures to evaluate their performance, all of which could
reduce the usefulness of our non-GAAP financial measures.
The calculations and reconciliations of historic adjusted
EBITDA, adjusted net income (loss), and adjusted EPS to net income
(loss), the most directly comparable financial measure stated in
accordance with GAAP, are provided below and in the accompanying
financial tables. Investors are encouraged to review the
reconciliations and not to rely on any single financial measure to
evaluate our business.
We have not reconciled adjusted EBITDA guidance to net income
(loss) because we do not provide guidance for net income (loss) or
for items that we do not consider indicative of our ongoing
performance, including, but not limited to, the impact of
significant non-recurring items, as certain of these items are out
of our control and/or cannot be reasonably predicted. Accordingly,
reconciliations of adjusted EBITDA guidance to the corresponding
U.S. GAAP measures are not available without unreasonable
effort.
Adjusted EBITDA
We calculate adjusted EBITDA as net
income (loss) adjusted to exclude (i) depreciation and
amortization, (ii) interest income, (iii) interest expense, (iv)
income tax (benefit) expense, (v) loss on extinguishment of debt,
(vi) other (income) expense (non-operating), (vii) share-based
compensation, (viii) warrants issued with revenue contracts, (ix)
amortization of non-cash payment for research and development, (x)
net costs associated with exiting contracts, (xi) non-operating,
non-recurring costs, (xii) reorganizational and severance costs,
and (xiii) acquisition-related costs. We do not view the items
excluded as representative of our ongoing operations.
Adjusted Net Income (Loss)
We calculate adjusted net
income (loss) as net income (loss) attributable to Sharecare, Inc.
adjusted to exclude (i) amortization of acquired intangibles, (ii)
amortization of deferred financing fees, (iii) change in fair value
of warrant liability and contingent consideration, (iv) share-based
compensation, (v) warrants issued with revenue contracts, (vi)
amortization of non-cash payment for research and development,
(vii) net costs associated with exiting contracts, (viii)
non-operating, non-recurring costs, (ix) reorganizational and
severance costs, and (x) acquisition related costs. We do not view
the items excluded as representative of our ongoing operations.
Adjusted Earnings (Loss) Per Share
We calculate
adjusted EPS as adjusted net income (loss), as defined above,
divided by the number of weighted average common shares outstanding
- basic and diluted.
About Sharecare
Sharecare is the leading digital
health company that helps people – no matter where they are in
their health journey – unify and manage all their health in one
place. Our comprehensive and data-driven virtual health platform is
designed to help people, providers, employers, health plans,
government organizations, and communities optimize individual and
population-wide well-being by driving positive behavior change.
Driven by our philosophy that we are all together better, at
Sharecare, we are committed to supporting each individual through
the lens of their personal health and making high-quality care more
accessible and affordable for everyone. To learn more, visit
www.sharecare.com.
Important Notice Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 that are based on beliefs and
assumptions and on information currently available. In some cases,
you can identify forward-looking statements by the following words:
"outlook," "target," "reflect," "on track," "foresees," "future,"
"may," "deliver," "will," "shall," "could," "would," "should,"
"expect," "intend," "plan," "anticipate," "believe," "estimate,"
"predict," "project," "potential," "continue," "ongoing" or the
negative of these terms, other comparable terminology (although not
all forward-looking statements contain these words), or by
discussions of strategy, plans, or intentions. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. Although we believe that we
have a reasonable basis for each forward-looking statement
contained in this press release, we caution you that these
statements are based on a combination of facts and factors
currently known by us and our projections of the future, about
which we cannot be certain.
Forward-looking statements in this press release include, but
are not limited to, our ability to realize the expected benefits of
partnerships or other relationships with third parties or customers
on our future growth objectives and statements regarding our future
outlook, including those under the caption "Financial Outlook."
We cannot assure you that the forward-looking statements in this
press release will prove to be accurate. These forward-looking
statements are subject to a number of significant risks and
uncertainties that could cause actual results to differ materially
from expected results. Descriptions of some of the factors that
could cause actual results to defer materially from these
forward-looking statements are discussed in more detail in our
filings with the U.S. Securities and Exchange Commission (the
"SEC"), including the Risk Factors section of the Annual Report on
Form 10-K. Furthermore, if the forward-looking statements prove to
be inaccurate, the inaccuracy may be material. In light of the
significant uncertainties in these forward-looking statements, you
should not regard these statements as a representation or warranty
by us or any other person that we will achieve our objectives and
plans in any specified time frame, or at all. The forward-looking
statements in this press release represent our views as of the date
of this press release. We anticipate that subsequent events and
developments will cause our views to change. However, while we may
elect to update these forward-looking statements at some point in
the future, we have no current intention of doing so except to the
extent required by applicable law. You should, therefore, not rely
on these forward-looking statements as representing our views as of
any date subsequent to the date of this press release.
In addition, there can be no assurance that the strategic review
process will result in any transaction, or if a transaction is
undertaken, as to its terms or timing, and the company does not
intend to provide additional information on the strategic review
until it determines that additional disclosure is appropriate or
necessary.
Media Relations:
Jen Martin
Hall
jen@sharecare.com
Investor Relations:
Bob
East
SharecareIR@westwicke.com
SHARECARE,
INC.
|
CONSOLIDATED
STATEMENTS OF OPERATIONS
|
(In thousands,
except share and per share amounts)
|
|
|
Three Months
Ended
December 31,
|
|
Year Ended December
31,
|
|
2022
|
|
2021
|
|
2022
|
|
2021
|
|
(unaudited)
|
|
(unaudited)
|
|
|
|
|
Revenue
|
$
123,262
|
|
$
118,537
|
|
$
442,415
|
|
$
412,815
|
Costs and operating
expenses:
|
|
|
|
|
|
|
|
Costs of revenue
(exclusive of depreciation and amortization below)
|
73,241
|
|
58,935
|
|
238,293
|
|
203,218
|
Sales and
marketing
|
15,172
|
|
15,360
|
|
55,870
|
|
51,407
|
Product and
technology
|
16,290
|
|
21,838
|
|
70,527
|
|
74,438
|
General and
administrative
|
33,770
|
|
51,534
|
|
171,811
|
|
136,594
|
Depreciation and
amortization
|
12,425
|
|
10,000
|
|
45,256
|
|
32,601
|
Total costs and
operating expenses
|
150,898
|
|
157,667
|
|
581,757
|
|
498,258
|
Loss from
operations
|
(27,636)
|
|
(39,130)
|
|
(139,342)
|
|
(85,443)
|
|
|
|
|
|
|
|
|
Other income
(expense):
|
|
|
|
|
|
|
|
Interest
income
|
1,417
|
|
47
|
|
1,867
|
|
96
|
Interest
expense
|
(852)
|
|
(721)
|
|
(2,431)
|
|
(27,662)
|
Loss on extinguishment
of debt
|
—
|
|
—
|
|
—
|
|
(1,148)
|
Other
income
|
2,925
|
|
47,822
|
|
20,215
|
|
27,007
|
Total other income
(expense)
|
3,490
|
|
47,148
|
|
19,651
|
|
(1,707)
|
Income (loss) before
income tax benefit (expense)
|
(24,146)
|
|
8,018
|
|
(119,691)
|
|
(87,150)
|
Income tax benefit
(expense)
|
(59)
|
|
1,501
|
|
206
|
|
2,021
|
Net income
(loss)
|
(24,205)
|
|
9,519
|
|
(119,485)
|
|
(85,129)
|
Net loss attributable
to non-controlling interest in subsidiaries
|
(81)
|
|
(98)
|
|
(778)
|
|
(129)
|
Net income (loss)
attributable to Sharecare, Inc.
|
$
(24,124)
|
|
$
9,617
|
|
$
(118,707)
|
|
$
(85,000)
|
|
|
|
|
|
|
|
|
Net earnings (loss) per
share attributable to common stockholders:
|
|
|
|
|
|
|
|
Basic
|
$
(0.07)
|
|
$
0.03
|
|
$
(0.34)
|
|
$
(0.30)
|
Diluted
|
$
(0.07)
|
|
$
0.02
|
|
$
(0.34)
|
|
$
(0.30)
|
|
|
|
|
|
|
|
|
Weighted-average common
shares outstanding:
|
|
|
|
|
|
|
|
Basic
|
350,688,872
|
|
336,534,375
|
|
348,103,491
|
|
281,026,365
|
Diluted
|
350,688,872
|
|
411,141,721
|
|
348,103,491
|
|
281,026,365
|
SHARECARE,
INC.
|
CONSOLIDATED BALANCE
SHEETS
|
(In thousands,
except share and per share amounts)
|
|
|
As of December
31,
|
|
2022
|
|
2021
|
Assets
|
|
|
|
Current
assets:
|
|
|
|
Cash and cash
equivalents
|
$
182,508
|
|
$
271,105
|
Accounts receivable,
net (net of allowance for doubtful accounts of $7,197 and $6,212,
respectively)
|
116,877
|
|
103,256
|
Other
receivables
|
4,114
|
|
5,327
|
Prepaid
expenses
|
12,612
|
|
8,819
|
Other current
assets
|
4,515
|
|
2,459
|
Total current
assets
|
320,626
|
|
390,966
|
Property and
equipment, net
|
5,082
|
|
4,534
|
Other long-term
assets
|
20,362
|
|
12,173
|
Intangible assets,
net
|
163,114
|
|
155,086
|
Goodwill
|
191,817
|
|
192,442
|
Total
assets
|
$
701,001
|
|
$
755,201
|
Liabilities,
Redeemable Convertible Preferred Stock and Stockholders'
Equity
|
|
|
|
Current
liabilities:
|
|
|
|
Accounts
payable
|
$
8,838
|
|
$
27,155
|
Accrued expenses and
other current liabilities
|
81,627
|
|
51,653
|
Deferred
revenue
|
9,032
|
|
11,655
|
Contract liabilities,
current
|
1,535
|
|
4,597
|
Total current
liabilities
|
101,032
|
|
95,060
|
Contract liabilities,
noncurrent
|
—
|
|
1,745
|
Warrant
liabilities
|
2,441
|
|
10,820
|
Long-term
debt
|
—
|
|
419
|
Other long-term
liabilities
|
16,723
|
|
24,116
|
Total
liabilities
|
120,196
|
|
132,160
|
Commitments and
contingencies
|
|
|
|
Series A redeemable
convertible preferred stock, $0.0001 par value; 5,000,000 shares
authorized; 5,000,000 shares issued and outstanding, aggregate
liquidation preference of $50,000 as of December 31, 2022 and
2021
|
58,205
|
|
58,205
|
Stockholders'
equity:
|
|
|
|
Common stock, $0.0001
par value; 600,000,000 and 600,000,000 shares authorized;
345,463,620 and 345,788,707 shares issued and outstanding as of
December 31, 2022 and 2021, respectively
|
35
|
|
35
|
Additional paid-in
capital
|
1,120,024
|
|
1,042,164
|
Accumulated other
comprehensive loss
|
(2,794)
|
|
(2,061)
|
Accumulated
deficit
|
(595,820)
|
|
(477,113)
|
Total Sharecare, Inc.
stockholders' equity
|
521,445
|
|
563,025
|
Noncontrolling
interest in subsidiaries
|
1,155
|
|
1,811
|
Total stockholders'
equity
|
522,600
|
|
564,836
|
Total liabilities,
redeemable convertible preferred stock and stockholders'
equity
|
$
701,001
|
|
$
755,201
|
SHARECARE,
INC.
|
RECONCILIATION OF
GAAP NET INCOME (LOSS) TO ADJUSTED EBITDA
|
(Unaudited)
|
(In
thousands)
|
|
|
|
Three Months
Ended
December 31,
|
|
Year Ended
December 31,
|
|
|
2022
|
|
2021
|
|
2022
|
|
2021
|
Net income
(loss)
|
|
$
(24,205)
|
|
$
9,519
|
|
$
(119,485)
|
|
$
(85,129)
|
Add:
|
|
|
|
|
|
|
|
|
Depreciation and
amortization
|
|
12,425
|
|
10,000
|
|
45,256
|
|
32,601
|
Interest
income
|
|
(1,417)
|
|
(47)
|
|
(1,867)
|
|
(96)
|
Interest
expense
|
|
852
|
|
721
|
|
2,431
|
|
27,662
|
Income tax (benefit)
expense
|
|
59
|
|
(1,501)
|
|
(206)
|
|
(2,021)
|
Loss on extinguishment
of debt
|
|
—
|
|
—
|
|
—
|
|
1,148
|
Other income
|
|
(2,925)
|
|
(47,822)
|
|
(20,215)
|
|
(27,007)
|
Share-based
compensation
|
|
8,009
|
|
21,263
|
|
69,628
|
|
46,780
|
Warrants issued with
revenue contracts(a)
|
|
14
|
|
20
|
|
62
|
|
79
|
Amortization of
non-cash payment for research and development
|
|
1,190
|
|
423
|
|
2,460
|
|
1,235
|
Net costs associated
with exiting contracts(b)
|
|
353
|
|
—
|
|
3,839
|
|
—
|
Non-operating,
non-recurring costs(c)
|
|
4,514
|
|
9,868
|
|
14,360
|
|
10,592
|
Reorganizational and
severance costs(d)
|
|
4,637
|
|
538
|
|
13,681
|
|
1,504
|
Acquisition-related
costs
|
|
1,088
|
|
2,373
|
|
5,832
|
|
19,680
|
Adjusted
EBITDA(e)
|
|
$
4,594
|
|
$
5,355
|
|
$
15,776
|
|
$
27,028
|
|
|
|
|
(a)
|
Represents the non-cash
value of warrants issued to clients for meeting specific revenue
thresholds.
|
|
(b)
|
For the year ended
December 31, 2022, previously undisclosed first quarter net costs
were included for comparability purposes and to display trends
associated with exiting contracts during the period.
|
|
(c)
|
For 2022, primarily
represents costs related to the settlement of legal obligations,
new business opportunities, and lease termination. For 2021,
primarily represents costs related to the settlement of legal
obligations.
|
|
(d)
|
For 2022, primarily
represents costs related to globalizing a portion of the workforce
and severance. For 2021, primarily represents costs related to
severance.
|
|
(e)
|
Includes non-cash
amortization associated with contract liabilities recorded in
connection with acquired businesses.
|
SHARECARE,
INC.
|
RECONCILIATION OF
GAAP NET INCOME (LOSS) ATTRIBUTABLE TO SHARECARE TO
ADJUSTED NET LOSS AND ADJUSTED LOSS PER SHARE
|
(Unaudited)
|
(In thousands,
except share and per share data)
|
|
|
|
Three Months
Ended
December 31,
|
|
Year Ended
December 31,
|
|
|
2022
|
|
2021
|
|
2022
|
|
2021
|
Net income (loss)
attributable to Sharecare, Inc.
|
|
$
(24,124)
|
|
$
9,617
|
|
$ (118,707)
|
|
$
(85,000)
|
Add:
|
|
|
|
|
|
|
|
|
Amortization of
acquired intangibles(a)
|
|
1,631
|
|
1,668
|
|
6,526
|
|
5,321
|
Amortization of
deferred financing fees
|
|
71
|
|
71
|
|
280
|
|
15,537
|
Change in fair value of
warrant liability and contingent consideration
|
|
(2,727)
|
|
(47,842)
|
|
(18,492)
|
|
(26,123)
|
Share-based
compensation
|
|
8,009
|
|
21,263
|
|
69,628
|
|
46,780
|
Warrants issued with
revenue contracts(b)
|
|
14
|
|
20
|
|
62
|
|
79
|
Amortization of
non-cash payment for research and development
|
|
1,190
|
|
423
|
|
2,460
|
|
1,235
|
Net costs associated
with exiting contracts(c)
|
|
353
|
|
—
|
|
3,839
|
|
—
|
Non-operating,
non-recurring costs(d)
|
|
4,514
|
|
9,868
|
|
14,360
|
|
10,592
|
Reorganizational and
severance costs(e)
|
|
4,637
|
|
538
|
|
13,681
|
|
1,504
|
Acquisition-related
costs
|
|
1,088
|
|
2,373
|
|
5,832
|
|
19,680
|
Adjusted net
loss(f)
|
|
$
(5,344)
|
|
$
(2,001)
|
|
$
(20,531)
|
|
$
(10,395)
|
|
|
|
|
|
|
|
|
|
Weighted-average common
shares outstanding, basic and diluted
|
|
350,688,872
|
|
336,534,375
|
|
348,103,491
|
|
281,026,365
|
|
|
|
|
|
|
|
|
|
Adjusted loss per
share, basic and diluted
|
|
$
(0.02)
|
|
$
(0.01)
|
|
$
(0.06)
|
|
$
(0.04)
|
|
|
|
|
(a)
|
Represents non-cash
expenses related to the amortization of intangibles in connection
with acquired businesses.
|
|
(b)
|
Represents the non-cash
value of warrants issued to clients for meeting specific revenue
thresholds.
|
|
(c)
|
For the year ended
December 31, 2022, previously undisclosed first quarter net costs
were included for comparability purposes and to display trends
associated with exiting contracts during the period.
|
|
(d)
|
For 2022, primarily
represents costs related to the settlement of legal obligations,
new business opportunities, and lease termination. For 2021,
primarily represents costs related to the settlement of legal
obligations.
|
|
(e)
|
For 2022, primarily
represents costs related to globalizing a portion of the workforce
and severance. For 2021, primarily represents costs related to
severance.
|
|
(f)
|
The income tax effect
of the Company's non-GAAP reconciling items are offset by valuation
allowance adjustments of the same amount given the Company is in a
full valuation allowance position.
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sharecare-announces-fourth-quarter-and-full-year-2022-financial-results-and-operational-highlights-301784349.html
SOURCE Sharecare